Governance Documents

The Board of Directors of GI Dynamics (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Management Team


Scott Schorer, President and Chief Executive Officer

Scott brings over 20 years of executive experience in the medical device industry, having both founded and helmed numerous public and private companies in the medical device, biologics and healthcare IT space.

Scott served as a president and consultant to numerous boards and CEOs across a wide variety of companies in the medical device, biologics and related markets. He has raised ~ $150m in equity in public and private entities. Scott currently serves on the Advamed Board of Directors and the Advamed Accel Board of Directors.

Prior to joining GI Dynamics, Scott served as a turnaround executive working on behalf of multiple venture capital and private equity firms. Scott served as President, Americas of Systagenix, the private equity buyout of the J&J Advanced Wound Care Division- sold to Acelity. Scott led the uplisting of PlasmaTech Biologics from the OTC to Nasdaq, and founded and led Innovative Spinal Technologies prior to its sale to Integra. Scott founded and led CentriMed, which was sold to the Global Healthcare Exchange (GHX). GHX transacted over $45bn in 2018 and has saved member organizations over $5bn since inception.

Scott began his medical device career as a sales representative for a surgical distributor, working for Anspach and Carl Zeiss. Scott served as a Scout Platoon Leader and Rifle Platoon Leader in the 82nd Airborne Division.

Scott holds a Bachelor of Arts and Bachelor of Engineering from Dartmouth College.


Charles Carter, Chief Financial Officer

Charles brings over 15 years of experience as a finance executive in the medical industry, having worked with a wide variety of life sciences, therapeutics, and medical device companies.

Charles has been serving as a consulting finance executive to a broad array of life sciences companies for Danforth Advisors, LLC since February 2018, and previously from 2012 to 2015. In 2015, Charles joined the Guild for Human Services, Inc., as CFO then returned to Danforth Advisors to resume consulting for life science companies in February 2018.

During his time with Danforth, Charles has served as a senior finance executive for Marina Biotech (NASDAQ: MRNA) and Interleukin Genetics (NASDAQ: ILGN) and continues to serve as the head of finance for numerous privately and venture backed life science companies.

Prior to joining Danforth in 2012, Charles held the position of CFO for Aeris Therapeutics, Inc. and Intelligent Medical Devices, Inc., vice president of finance for Adnexus Therapeutics, Inc., and senior director of financial planning and analysis for Transkaryotic Therapies, Inc. (NASDAQ: TKT).

Charles holds an MBA and MS degree in Molecular Genetics and Cell Biology from the University of Chicago and a BS in Biology from Colgate University.


Stephen Linhares, Vice President of Clinical & Regulatory Affairs

Stephen brings over 30 years of experience in development, regulatory, preclinical and clinical operations, quality and resource management with a focus on medical devices.

Prior to joining GI Dynamics, Stephen held the positions of vice president of regulatory, clinical affairs and quality assurance at Neograft Technologies Inc. and leadership roles at Insulet Corporation, Boston Scientific Corporation Inc., and Phase Forward Inc., as well as vice president roles at PLC Medical Systems.

Stephen brings extensive knowledge of the diabetes disease and medical device space, where he has led 10 clinical trials, multiple CE Mark approvals, and numerous 510(k) clearances. Stephen holds nearly 20 United States and international patents and co-author of two peer-reviewed publications.

Stephen holds a BS in Physics from Bridgewater State College.

Board of Directors

The GI Dynamics board is committed to carrying out our mission of improving the lives of people suffering from the global epidemics of type 2 diabetes and obesity through the development and commercialization of breakthrough treatments.


Daniel J. Moore (Chairman)

Daniel Moore is Chairman of the Board for LivaNova [NASDAQ: LIVN]. Mr. Moore previously held the position as president and chief executive officer of Cyberonics [NASDAQ: CYBX] from 2007 to 2015, when the company merged with Sorin to form LivaNova. Mr. Moore joined Cyberonics after 18 years at Boston Scientific [NYSE: BSX] where he was the president of InterContinental. He also serves on the boards of the Epilepsy Foundation of America, BioHouston and the Advisory Board of Purdue University’s Weldon School of Biomedical Engineering.

Prior company boards include TriVascular [NASDAQ: TRIV] which was sold to Endologix and Topera which was sold to Abbott. He also served on the boards of BrainScope Company, Inc., Medical Device Manufacturers Association (past-Chair), Medical Device Innovation Consortium, Epilepsy Foundation of Texas (past- Chair) and Smiling Kids Inc.


Oern Stuge, MD, MBA, Dr.

Dr. Stuge, MD, MBA, brings significant experience in medical devices and specifically in type 2 diabetes and obesity. He has also lead successful clinical development programs and global commercialization efforts and has held executive and board positions with numerous medical device companies over the past 30 years. As director, he has helped lead several successful company exits, raised significant capital and launched an IPO.


Juliet Thompson

Ms. Thompson has advised and raised capital for healthcare companies for more than 20 years and founded Code Securities, a healthcare investment banking firm that was sold to Nomura. In addition to GI Dyanmics, Thompson also serves as NED for Nexstim Limited, NED for Novacyt SA, and is the chair of Premier Veterinary Group Plc.


Praveen Tyle, PhD, Dr.

Praveen Tyle, PhD, brings extensive knowledge in research and development from the pharmaceutical, consumer health and medical device industry.

Dr. Tyle is currently the executive vice president of research and development at Lexicon. He previously held the position as member of the executive management team for Osmotica Pharmaceutical Corp., where his last held position was president and chief executive officer, prior to that he served as executive vice president and chief scientific officer.

Prior to Osmotica, Dr. Tyle held a series of scientific leadership positions within the pharmaceutical industry, with the United States Pharmacopeia, Novartis OTC, Bausch & Lomb Incorporated and Pharmacia Corporation. Dr. Tyle also serves as director of Eyegate Pharmaceuticals, Inc. and Orient Europharma Ltd.

Dr. Tyle received his B.Pharm. (honors) from the Indian Institute of Technology, Banaras Hindu University and his Ph.D. in pharmaceutics and pharmaceutical chemistry from the Ohio State University.

Committee Composition

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.